The GLP-1 Wave: What Self-Funded Employers Need to Know About Pharmacy Spend
For years, diabetes and its downstream complications have been among the largest cost drivers for self-funded employer health plans. Now, a new class of medications is reshaping that picture entirely — and not in the way most employers expect.
GLP-1 receptor agonists — drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — have quickly become some of the most prescribed medications in the country. Originally approved for Type 2 diabetes management, these drugs have expanded into obesity treatment, cardiovascular risk reduction, and even sleep apnea. The clinical results are compelling. The cost implications for self-funded employers are staggering.
The Spend Is Already Here
Across employer health plans, GLP-1s have exploded from a niche pharmacy line item to a top-three — often top-one — driver of pharmacy spend. Annual costs per member on a GLP-1 can exceed $12,000 to $15,000, and that figure doesn’t account for the monitoring, labs, and follow-up care that often accompany treatment. For a self-funded employer with even a modest number of members on these agents, the budget impact can reach six or seven figures quickly.
What makes this particularly acute for self-funded groups is that there’s no insurer absorbing the shock. Every claim hits the plan directly. Employers operating on thin stop-loss corridors or with aggregate exposure are especially vulnerable as utilization climbs.
Diabetes Management: The Upstream Problem
Before GLP-1s dominated the conversation, unmanaged and poorly managed diabetes was already quietly eroding plan budgets. The costs of insulin, CGM devices, oral hypoglycemics, and diabetes-related complications — neuropathy, nephropathy, retinopathy, cardiovascular events — compound year over year. A member with uncontrolled Type 2 diabetes can cost two to four times more than a controlled counterpart, not just in pharmacy but across medical spend.
GLP-1s sit at the intersection of pharmacy spend and chronic disease management. That’s both the problem and the opportunity. When used appropriately for members with clinical need, these agents can reduce downstream complications, hospitalizations, and cardiovascular events — costs that dwarf the price of the medication itself. When prescribed broadly, without clinical oversight or adherence tracking, they generate enormous spend with limited population-level return.
What’s Driving Utilization
Several forces are accelerating GLP-1 adoption in employer populations. Direct-to-consumer advertising has driven patient demand. Telehealth platforms have made prescriptions more accessible than ever. And with obesity now an approved indication, the eligible population has grown from roughly 10–12% of a typical employee base to potentially 40% or more.
Employers who haven’t yet felt the full impact are often one plan year away from it.
The Awareness Gap
Many self-funded employers are still operating with last year’s pharmacy data. By the time a renewal lands, the trajectory is already steep. Understanding the scope of GLP-1 exposure, how diabetes is being managed across the population, and where clinical and financial risk is concentrated is no longer a back-office exercise — it’s a core benefits strategy question.
The employers asking those questions now will be in a far better position than those who wait until the renewal conversation forces the issue.
What Employers Can Do: A Management Framework
The good news is that self-funded employers have more levers than fully-insured groups. The challenge is knowing which ones to pull — and in what order.
Start with your data. Before implementing any strategy, pull a current pharmacy utilization report segmented by therapeutic class. Know exactly how many members are on GLP-1s, what they’re being prescribed for (diabetes vs. obesity vs. off-label), what it’s costing per member per year, and what the trend looks like quarter over quarter. Without this baseline, every other decision is guesswork.
Implement clinical criteria and prior authorization. Plans that have seen the most success managing GLP-1 spend have established clear clinical coverage criteria — typically requiring a documented diagnosis, a minimum BMI threshold, evidence of a prior treatment attempt, and enrollment in a structured lifestyle or disease management program. Prior authorization tied to these criteria doesn’t eliminate access; it ensures the spend is clinically justified. Work with your PBM to make sure edits are active and enforced.
Invest in diabetes management programs. The highest-value intervention for many plans isn’t restricting GLP-1 access — it’s making sure members who need them get the support to use them effectively, while moving lower-acuity members toward equally effective, lower-cost alternatives. Structured diabetes management programs, including remote monitoring, pharmacist coaching, and care navigation, can improve outcomes and reduce total cost of care even when GLP-1 utilization remains elevated.
Evaluate your PBM contract and formulary positioning. GLP-1 rebates vary significantly by drug and by PBM contract. Formulary placement — whether a drug sits on Tier 2, Tier 3, or requires step therapy — has a direct impact on both utilization and net cost. Many employers are paying list price exposure on drugs where rebate negotiation could materially reduce net plan cost. If your PBM contract hasn’t been benchmarked recently, this is the year to do it.
Address stop-loss implications proactively. High-cost GLP-1 claimants can approach or exceed individual stop-loss attachment points, particularly when combined with other conditions. Carriers are beginning to scrutinize GLP-1 exposure at renewal, and some are adding specific carve-outs or lasers. Knowing your exposure before the renewal conversation gives you negotiating leverage and time to implement controls.
Don’t wait for the crisis. The employers managing this well aren’t doing anything exotic — they’re reviewing pharmacy data quarterly, enforcing clinical criteria, holding their PBM accountable, and treating chronic disease management as a cost-containment strategy rather than a wellness nicety. The ones struggling are those who treated GLP-1s as a temporary trend and now face multi-year cost trajectories that are difficult to bend quickly.
Self-funded employers have real flexibility that fully-insured groups don’t. The window to use it effectively is now — before the spend curve becomes the new baseline.